What is Tesamorelin?
Tesamorelin is described as an analogue of growth hormone-releasing hormone (GHRH), also called growth hormone-releasing factor (GRF). It prompts the body’s own growth-hormone signalling rather than being administered growth hormone, which is why IGF-I is measured as part of the studied response.
Key concepts: Receptor · Agonist · Comparator
How it works and what researchers study
The relevant clinical research measured visceral adipose tissue by imaging in a defined patient population, alongside hormone markers, withdrawals and adverse events over a fixed study period.
What the evidence shows
A 2007 randomized trial in 412 patients with HIV and abdominal fat accumulation, over 26 weeks, reported reduced visceral fat and increased IGF-I in that population, with more withdrawals due to adverse events.
Limits of the evidence
- Visceral fat is a specific compartment; the result is not a general weight-loss or body-composition claim.
- The finding belongs to the enrolled patient population and its 26-week duration, and supports no physique or performance use.
- We assert no Canadian authorization status; check the current Health Canada Drug Product Database record.
References
- Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007. doi:10.1056/NEJMoa072375 View source
- Health Canada. Drug Product Database: the official list of drug products authorized for sale in Canada. View source
